Cargando…

Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy

SIMPLE SUMMARY: Adjuvant chemotherapy following radical cystectomy is a common therapy for muscle invasive bladder cancer (MIBC) patients. No applicable biomarkers exist to predict which patients will benefit from chemotherapy. Three immune cell markers, the chemokine CC motif ligand 2 (CCL2), the p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taubert, Helge, Eckstein, Markus, Epple, Elena, Jung, Rudolf, Weigelt, Katrin, Lieb, Verena, Sikic, Danijel, Stöhr, Robert, Geppert, Carol, Weyerer, Veronika, Bertz, Simone, Kehlen, Astrid, Hartmann, Arndt, Wullich, Bernd, Wach, Sven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829767/ https://www.ncbi.nlm.nih.gov/pubmed/33467469 http://dx.doi.org/10.3390/cells10010159

Ejemplares similares

CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage
por: Eckstein, Markus, et al.
Publicado: (2020)

Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort
por: Weyerer, Veronika, et al.
Publicado: (2021)

Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients
por: Eckstein, Markus, et al.
Publicado: (2018)

Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients
por: Eckstein, Markus, et al.
Publicado: (2021)

Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy
por: Eckstein, Markus, et al.
Publicado: (2020)

Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
por: Weyerer, Veronika, et al.
Publicado: (2021)

Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis
por: Kubon, Jennifer, et al.
Publicado: (2020)

TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers
por: Weyerer, Veronika, et al.
Publicado: (2021)

Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients
por: Abdulrahman, Amer, et al.
Publicado: (2019)

Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype
por: Weyerer, Veronika, et al.
Publicado: (2020)

Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer Patients
por: König, Paul, et al.
Publicado: (2020)

High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2021)

Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
por: Keck, Bastian, et al.
Publicado: (2013)

Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma
por: Bellut, Julia, et al.
Publicado: (2017)

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis
por: Sikic, Danijel, et al.
Publicado: (2017)

The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2021)

Endogenous Retroviral–K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma
por: Weyerer, Veronika, et al.
Publicado: (2021)

FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy
por: Sikic, Danijel, et al.
Publicado: (2020)

Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients
por: Lieb, Verena, et al.
Publicado: (2021)

Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of Prostate Cancer Patients
por: Lieb, Verena, et al.
Publicado: (2022)

Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort
por: Kullmann, Friederike, et al.
Publicado: (2023)

Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients
por: Fichte, Alexander, et al.
Publicado: (2022)

Reduced Recurrence Rates Are Associated with Photodynamic Diagnostics Compared to White Light after Extended Transurethral Resection of Bladder Tumors
por: Marquardt, Alexander, et al.
Publicado: (2022)

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy
por: Eckstein, Markus, et al.
Publicado: (2018)

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2017)

Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
por: Kahlmeyer, Andreas, et al.
Publicado: (2019)

Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo
por: Wach, Sven, et al.
Publicado: (2019)

RNA Sequencing of Collecting Duct Renal Cell Carcinoma Suggests an Interaction between miRNA and Target Genes and a Predominance of Deregulated Solute Carrier Genes
por: Wach, Sven, et al.
Publicado: (2019)

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts
por: Sikic, Danijel, et al.
Publicado: (2019)

Expression of GP88 (progranulin) in serum of prostate cancer patients is associated with Gleason scores and overall survival
por: Greither, Thomas, et al.
Publicado: (2018)

Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients
por: Stöhr, Christine G., et al.
Publicado: (2019)

Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
por: Krumbholz, Manuela, et al.
Publicado: (2019)

Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions
por: Keck, Bastian, et al.
Publicado: (2021)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
por: Klümper, Niklas, et al.
Publicado: (2023)

Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients
por: Lieb, Verena, et al.
Publicado: (2017)

MicroRNA profiles classify papillary renal cell carcinoma subtypes
por: Wach, S, et al.
Publicado: (2013)

HLA-E expression and its clinical relevance in human renal cell carcinoma
por: Seliger, Barbara, et al.
Publicado: (2016)

Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients
por: Stoehr, C G, et al.
Publicado: (2016)

The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors
por: Jasinski-Bergner, Simon, et al.
Publicado: (2022)

The arguments for an early cystectomy in patients with urothelial carcinoma
por: Barski, Dimitri
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r6khuj03k2k27ubc33ah064ef7